Contribution of the addition of anti-ββ2-glycoprotein to the classification of antiphospholipid syndrome in predicting adverse pregnancy outcome

被引:5
作者
Oron, Galia [4 ]
Ben-Haroush, Avi [1 ,4 ]
Goldfarb, Rachel [4 ]
Molad, Yair [2 ,4 ]
Hod, Moshe [4 ]
Bar, Jacob [3 ,4 ]
机构
[1] Helen Schneider Hosp Women, Rabin Med Ctr, Perinatal Div, IL-49100 Petah Tiqwa, Israel
[2] Rabin Med Ctr, Rheumatol Unit, Lupus Clin, Petah Tiqwa, Israel
[3] Wolfson Med Ctr, Perinatal Div, Holon, Israel
[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
Anti-beta; 2; glycoprotein; 1; antiphospholipid syndrome; pregnancy; complications; INTERNATIONAL CONSENSUS STATEMENT; SYSTEMIC-LUPUS-ERYTHEMATOSUS; EUROPEAN-FORUM; ANTIBODIES; CRITERIA; RISK; ANTI-BETA(2)-GLYCOPROTEIN-I; AUTOANTIBODIES; ASSOCIATION; UPDATE;
D O I
10.3109/14767058.2010.511339
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Methods. aEuro integral A retrospective cohort design was used. Ninety-one patients (total 394 pregnancies) referred to a tertiary medical center for evaluation of clinical features consistent with APS were divided into three groups: group A (n == 34), two positive tests for anticardiolipin (ACL) or lupus anticoagulant (LAC), in accordance with original APS classification (1998); group B (n == 18), two positive tests for a-beta beta 2GP1, in accordance with the revised APS criteria; and group C (n == 39), only one positive test for ACL or LAC. Results. aEuro integral Of the 52 women with APS (group A or B), 36 had primary disease, and 16 had secondary disease. On comparison of the groups, group B was characterized by a significantly higher rate of complicated pregnancy (83.3%%) than groups A (47.1%%) and C (76.9%%), P == 0.007, and a higher rate of fetal loss (72.2%%) than groups A ++ C (28.8%%, P == 0.001). Conclusions. aEuro integral The findings suggest that the revised APS criteria are preferable to the original classification for the prediction of complicated pregnancy.
引用
收藏
页码:606 / 609
页数:4
相关论文
共 50 条
  • [21] Anticardiolipin and anti-β2glycoprotein I immunoassays in the diagnosis of antiphospholipid syndrome
    Tincani, A
    Balestrieri, G
    Spatola, L
    Cinquini, M
    Meroni, PL
    Roubey, RAS
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1998, 16 (04) : 396 - 402
  • [22] Influence of anticardiolipin and anti-β2 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification
    Vanoverschelde, Laura
    Kelchtermans, Hilde
    Musial, Jacek
    de Laat, Bas
    Devreese, Katrien M. J.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2019, 3 (03) : 515 - 527
  • [23] Toward harmonized interpretation of anticardiolipin and anti-β2-glycoprotein -β 2-glycoprotein I antibody detection for diagnosis of antiphospholipid syndrome using defined fi ned level intervals and likelihood ratios: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
    Vandevelde, Arne
    Gris, Jean-Christophe
    Moore, Gary W.
    Musial, Jacek
    Zuily, Stephane
    Wahl, Denis
    Devreese, Katrien M. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (08) : 2345 - 2362
  • [24] Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus
    Tebo, Anne E.
    Willis, Rohan
    Jaskowski, Troy D.
    Guerra, Marta
    Pierangeli, Silvia S.
    Salmon, Jane
    Petri, Michelle
    Branch, D. Ware
    CLINICA CHIMICA ACTA, 2016, 460 : 107 - 113
  • [25] Anti-β2GPI domain 1 antibodies stratify high risk of thrombosis and late pregnancy morbidity in a large cohort of Chinese patients with antiphospholipid syndrome
    Liu, Tingting
    Gu, Jieyu
    Wan, Liyan
    Hu, Qiongyi
    Teng, Jialin
    Liu, Honglei
    Cheng, Xiaobing
    Ye, Junna
    Su, Yutong
    Sun, Yue
    Chi, Huihui
    Zhou, Zhuochao
    Jia, Jinchao
    Wang, Zhihong
    Zhou, Jinfeng
    Norman, Gary L.
    Wang, Xuefeng
    Yang, Chengde
    Shi, Hui
    THROMBOSIS RESEARCH, 2020, 185 : 142 - 149
  • [26] Pharmacokinetics of LJP 993, a tetrameric conjugate of domain 1 of β2-glycoprotein I for antiphospholipid syndrome
    Jia, L.
    Gu, Y.
    Zeng, E.
    Linnik, M. D.
    Jones, D. S.
    LUPUS, 2010, 19 (02) : 130 - 137
  • [27] Pathophysiology of β2-glycoprotein I in antiphospholipid syndrome
    Matsuura, E.
    Shen, L.
    Matsunami, Y.
    Quan, N.
    Makarova, M.
    Geske, F. J.
    Boisen, M.
    Yasuda, S.
    Kobayashi, K.
    Lopez, L. R.
    LUPUS, 2010, 19 (04) : 379 - 384
  • [28] β2-glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss
    Franklin, RD
    Hollier, N
    Kutteh, WH
    FERTILITY AND STERILITY, 2000, 73 (03) : 531 - 535
  • [29] β2-glycoprotein I, the playmaker of the antiphospholipid syndrome
    de Laat, HB
    Derksen, RHWM
    de Groot, PG
    CLINICAL IMMUNOLOGY, 2004, 112 (02) : 161 - 168
  • [30] Standardized antigen preparation to achieve comparability of anti-β2-glycoprotein I assays
    Mueller, Carolin
    Schlichtiger, Alice
    Balling, Gudrun
    Steigerwald, Udo
    Luppa, Peter B.
    Thaler, Markus
    THROMBOSIS RESEARCH, 2010, 126 (02) : E102 - E109